Article Sidebar
Published:
Oct 8, 2023Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Efficacy of Jade Wind-Barrier Powder in adjuvant treatment for children with asthma, and its influence on IFN-γ, immunoglobulin and mucin
Abstract
Purpose: To study the effects of Jade Wind-Barrier Powder on peripheral blood interferon-γ (INF-γ), immunoglobulin and sputum mucin in children with asthma.
Methods: Sixty-six children with asthma in remission stage were randomly separated into study and control groups. The control group was treated with budesonide formoterol powder inhaler, while the study group was orally administered Jade Wind-Barrier Powder. The therapeutic effects, and INF-γ, immunoglobulin and mucin levels in sputum, as well as pulmonary function parameters in both groups were determined. The number of acute relapses of asthma and duration of wheezing were counted in the patients. The relative effectiveness of Jade Wind-Barrier Powder in the treatment of asthma in the children was also assessed.
Results: The overall response rate (ORR) in the study group was 93.94 %, which was higher than in the control group (75.76 %, p < 0.05). Over the 6-month period of follow-up, the frequency of acute attacks of asthma in the study group was significantly lower while the duration of wheezing during attack was also shorter than in the control group. After treatment, pulmonary function indices in the study group were higher, whereas mucin 5AC (MUC5AC), mucin 5B (MUC5B) and mucin 1 (MUC1) levels in sputum were lower than in the control group (p < 0.05).
Conclusion: Jade Wind-Barrier Powder exerts therapeutic effect in children with asthma. However, further clinical trials across multi-centers are required to validate it its use in clinical practice.
